Antituberculous drugs.
D000014:Abnormalities, Drug-Induced / Q000453:epidemiology*; D000995:Antitubercular Agents / Q000009:adverse effects*; D004096:Dihydrostreptomycin Sulfate / Q000009:adverse effects; D004977:Ethambutol / Q000009:adverse effects; D005000:Ethionamide / Q000009:adverse effects; D005260:Female; D005333:Fetus / Q000187:drug effects*; D006311:Hearing Disorders / Q000151:congenital*; D006801:Humans; D007231:Infant, Newborn; D007538:Isoniazid / Q000009:adverse effects; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D012293:Rifampin / Q000009:adverse effects; D013307:Streptomycin / Q000009:adverse effects; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000995:Antitubercular Agents; D004977:Ethambutol; D005000:Ethionamide; D004096:Dihydrostreptomycin Sulfate; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin